Braingrid Limited Launches Data Intelligence Program for Precision Agriculture Growers including Cannabis Cultivators
Braingrid Limited (CSE:BGRD) (“Braingrid”), a global provider of affordable, scalable and easy-to-deploy sensor platforms for real-time data collection in Precision Agriculture, is pleased to announce that it has launched its new low-cost Data Analytics Program called Braingrid Data Intelligence. Reports generated under this program will provide growers with unprecedented conclusions on yield variances and leading indicators of pathogen risks before the actual outbreak occurs.
Braingrid Plant Data Scientist Dr. Vanessa Nielsen will lead the team responsible for producing all reports to cannabis customers. Dr. Nielsen commented “Our customers have always struggled with having sufficient time and expertise to analyze the mountain of data surrounding each batch. Now we will do the heavy lifting for them by digging into their grow details to discover hidden gems of information showing comparative batch-to-batch variations.”
As the “mobile field lab” supplier of real-time data, Braingrid becomes a valuable information partner providing new grow foresight.
Six reports are currently available to Braingrid customers: Anomaly Analysis for Temperature, Humidity, and CO2, Powdery Mildew and Spider Mite Scores, and Vapor Pressure Deficit Chart Analytics. More reports to be announced soon.
Braingrid’s recent agreement with integration partner A&L Canada Laboratories Inc. (“A&L”) will expand delivery of their tests such as Plant Tissue Reports to be part of Braingrid Data Intelligence. Nevin McDougall, President and Chief Commercial Officer of A&L, said: “Braingrid’s new analytical reports take the science of growing to a whole new level which, when combined with our various tests to confirm pathogens or fertility issues, give the grower unprecedented depth of knowledge and foresight.” The grower can then address the issue at hand and use this data in the next grow cycle for an even higher level of success. Anyone can grow a crop however A & L Canada Laboratories agronomy knowledge & testing services assists growers to achieve a higher yielding quality crop based on their specific goals.
Derek Pedro, Chief Cannabis Officer at WeedMD, commented: “Braingrid has been a valuable partner to WeedMD for years. These new reports provide a quick synopsis of detailed information over a period of months and years that was never before available to us, making what we do here more effective. We really appreciate this new view of our facility operation.”
Early indications from new and existing Braingrid customers show overwhelming support for these new low-cost reports. The Braingrid Data Intelligence program will be showcased at the upcoming O’Cannabiz Conference & Expo in Toronto on April 25-27, 2019.
Braingrid is a global technology company committed to the best interests of the precision agriculture industry for the long term. We provide valuable grow information by capturing real-time data using our technology platform to increase revenues, reduce costs, risks and improve yield – making it easier for the grower to operate efficiently and effectively. Braingrid is providing the cannabis industry with powerful technologies, now and into the future. The Company is listed on the CSE under the symbol BGRD.
This news release includes forward-looking information and statements, which may include, but are not limited to, information and statements regarding or inferring the future business, operations, financial performance, prospects, and other plans, intentions, expectations, estimates, and beliefs of Braingrid. Information and statements which are not purely historical fact are forward-looking statements. Forward-looking information and statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of Braingrid to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking information and statements herein. Although Braingrid believes that any forward-looking information and statements herein are reasonable, in light of the use of assumptions and the significant risks and uncertainties inherent in such information and statements, there can be no assurance that any such forward-looking information and statements will prove to be accurate, and accordingly readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance upon such forward-looking information and statements. Any forward-looking information and statements herein are made as of the date hereof, and except as required by applicable laws, Braingrid assumes no obligation and disclaims any intention to update or revise any forward-looking information and statements herein or to update the reasons that actual events or results could or do differ from those projected in any forward-looking information and statements herein, whether as a result of new information, future events or results, or otherwise, except as required by applicable laws.
The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.
To view an enhanced version of Figure 1, please visit:
In the evolving rush of mergers and acquisitions (M&A) in the Canadian cannabis market, Canopy Growth (NASDAQ:CGC,TSX:WEED) announced it will acquire The Supreme Cannabis Company (TSX:FIRE,OTCQX:SPRWF) in a deal worth approximately C$435 million.
Meanwhile, a cannabis operator in the US confirmed this week that it will receive a financial boost from a partner to solidify its position in the burgeoning Pennsylvania state market.
The Board of Directors of Aphria Unanimously Recommends Shareholders Vote “For” the Arrangement
Aphria to Host Special Meeting of Shareholders on Wednesday, April 14, 2021 to Approve Proposed Aphria-Tilray Business Combination
Love Hemp Group PLC (AQSE: LIFE) (OTCQB: WRHLF), one of the UK’s leading CBD and Hemp product suppliers, announces that as part of the equity fundraise announced yesterday, Antony Calamita and Andrew Male, Directors of the Company, subscribed for 285,714 Ordinary Shares and 1,428,571 Ordinary Shares respectively. The subscriptions are at a price of 3.5 pence per ordinary share for a total of £60,000. Following these subscriptions, Antony Calamita is now interested in 54,385,714 Ordinary Shares, representing 8.61% of the Company’s share capital as increased by the fundraising, and Andrew Male is now interested in 6,138,196 Ordinary Shares, representing 0.97% of the Company’s issued share capital as increased by the fundraising
Further, the timetable for receipt of applications under the Broker Option, which was also announced yesterday, has been extended until 5:00 pm 9 April 2021 to capture additional interest which was unable to be completed yesterday.
Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, would like to provide the following dial-in information for the Company’s upcoming Annual and Special Meeting (the “Meeting”) scheduled to be held at 11:00 a.m. Eastern Daylight Time on April 12, 2021. Shareholders and proxyholders may access the Meeting via teleconference by dialing 647-723-3984 or 1-866-365-4406 from Canada or the United States, then entering participation code “8487744” followed by the pound (“#”) sign.
In consideration of the COVID-19 pandemic and the recent restrictions imposed by the Ontario Provincial Government, shareholders and proxyholders will only be able to attend the Meeting via teleconference and will not be permitted to attend the Meeting in person at the address provided on the Notice of Annual and Special Meeting of Shareholders.
Gage Cannabis Announces Exclusive Partnership With Blue River to Bring Award-Winning Cannabis Extracts to Michigan
Gage Growth Corp. (“Gage” or the “Company”) (CSE:GAGE), a leading high-quality craft cannabis brand and operator in Michigan, announced today that it has signed an agreement with Blue River™ Extracts & Terpenes (“Blue River™”) to bring the brand’s award-winning solventless technology and other trademark branded products to the state’s medical patients and cannabis consumers. The Company will have exclusive rights to Blue River™’s premium product offerings in Michigan.